Ranolazine

This activity focuses on ranolazine, an FDA-approved medication for the management of chronic angina associated with ischemic heart disease. Aimed at optimizing the treatment of stable angina, the primary objective is to alleviate ischemic symptoms, minimize their occurrence, and reduce the risk of myocardial infarction and mortality. In conjunction with standard therapies such as aspirin, P2Y12 inhibitors, ACEIs, angiotensin receptor blockers, statins, beta-blockers, calcium channel blockers, and nitrates, ranolazine serves as an adjunct therapy, enriching the overall strategy for angina management.